Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

1. Glucocorticoids are widely used for the suppression of inflammation in chronic
inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disease …

Because of the central role of the transcription factor nuclear factor–κB (NF-κB) in cell
survival and proliferation in human multiple myeloma (MM), we explored the possibility of …

Numerous reports suggest that IL-6 promotes survival and proliferation of multiple myeloma
(MM) cells through the phosphorylation of a cell signaling protein, STAT3. Thus, agents that …

Purpose: Multiple myeloma remains an incurable malignancy of plasma cells despite
considerable advances in treatment. The purpose of the study was to develop novel …

Whether resveratrol, a component of red grapes, berries, and peanuts, could suppress the
proliferation of multiple myeloma (MM) cells by interfering with NF-κB and STAT3 pathways …

Histone deacetylases (HDACs) affect cell growth at the transcriptional level by regulating the
acetylation status of nucleosomal histones. HDAC inhibition induces differentiation and/or …

Purpose: The purpose of this study was to examine interactions between the proteasome
inhibitor bortezomib (Velcade) and the histone deacetylase (HDAC) inhibitors sodium …

Multiple myeloma (MM) remains incurable, with a median survival of 3 to 4 years. This study
shows direct effects of vascular endothelial growth factor (VEGF) upon MM and plasma cell …

Glucocorticoids are a backbone of treatment for multiple myeloma in both the upfront and
relapsed/refractory setting. While glucocorticoids have single agent activity in multiple …